{"id":"https://openalex.org/W2025422355","doi":"https://doi.org/10.1093/ajh/6.11.375s","title":"Pharmacokinetics of Fluvastatin and Specific Drug Interactions","display_name":"Pharmacokinetics of Fluvastatin and Specific Drug Interactions","alternate_titles":[],"publication_year":1993,"publication_date":"1993-11-01","ids":{"openalex":"https://openalex.org/W2025422355","doi":"https://doi.org/10.1093/ajh/6.11.375s","mag":"2025422355","pmid":"https://pubmed.ncbi.nlm.nih.gov/8297546"},"language":"en","primary_location":{"id":"doi:10.1093/ajh/6.11.375s","doi":"https://doi.org/10.1093/ajh/6.11.375s","is_oa":false,"landing_page_url":"https://doi.org/10.1093/ajh/6.11.375s","pdf_url":null,"source":{"id":"https://openalex.org/S128891601","display_name":"American Journal of Hypertension","issn_l":"0895-7061","issn":["0895-7061","1941-7225"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Hypertension","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2025422355"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018132398","display_name":"Harold T. Smith","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4388891806","display_name":"Sandoz Group AG (Switzerland)","ror":"https://ror.org/02rse7p59","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4388891806"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"H. T. Smith","raw_affiliation_strings":["Sandoz Research Institute, East Hanover, New Jersey 07936"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sandoz Research Institute, East Hanover, New Jersey 07936","institution_ids":["https://openalex.org/I4388891806"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032659696","display_name":"Leonard A. Jokubaitis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4388891806","display_name":"Sandoz Group AG (Switzerland)","ror":"https://ror.org/02rse7p59","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4388891806"]}],"countries":["CH"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"L. A. Jokubaitis","raw_affiliation_strings":["Sandoz Research Institute, East Hanover, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sandoz Research Institute, East Hanover, New Jersey","institution_ids":["https://openalex.org/I4388891806"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004945878","display_name":"August J. Troendle","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"A. J. Troendle","raw_affiliation_strings":["Medical Research Services, Cincinnati, Ohio"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Research Services, Cincinnati, Ohio","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080456114","display_name":"Dae-Yeon Hwang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4388891806","display_name":"Sandoz Group AG (Switzerland)","ror":"https://ror.org/02rse7p59","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4388891806"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"D. S. Hwang","raw_affiliation_strings":["Sandoz Research Institute, East Hanover, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sandoz Research Institute, East Hanover, New Jersey","institution_ids":["https://openalex.org/I4388891806"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5006479360","display_name":"W. T. Robinson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4388891806","display_name":"Sandoz Group AG (Switzerland)","ror":"https://ror.org/02rse7p59","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4388891806"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"W. T. Robinson","raw_affiliation_strings":["Sandoz Research Institute, East Hanover, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sandoz Research Institute, East Hanover, New Jersey","institution_ids":["https://openalex.org/I4388891806"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5032659696"],"corresponding_institution_ids":["https://openalex.org/I4388891806"],"apc_list":{"value":4814,"currency":"USD","value_usd":4814},"apc_paid":null,"fwci":4.1637,"has_fulltext":false,"cited_by_count":90,"citation_normalized_percentile":{"value":0.94058837,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":98},"biblio":{"volume":"6","issue":"11 Pt 2","first_page":"375S","last_page":"382S"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9106000065803528,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9106000065803528,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.07829999923706055,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11618","display_name":"Cholesterol and Lipid Metabolism","score":0.0034000000450760126,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fluvastatin","display_name":"fluvastatin","score":1.0},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9089999794960022},{"id":"https://openalex.org/keywords/drug-interactions","display_name":"drug interactions","score":0.8230000138282776},{"id":"https://openalex.org/keywords/statins","display_name":"statins","score":0.9919999837875366},{"id":"https://openalex.org/keywords/bioavailability","display_name":"bioavailability","score":0.7149999737739563},{"id":"https://openalex.org/keywords/food-effect","display_name":"food effect","score":0.6299999952316284},{"id":"https://openalex.org/keywords/liver-dysfunction","display_name":"liver dysfunction","score":0.7820000052452087},{"id":"https://openalex.org/keywords/cholestyramine","display_name":"cholestyramine","score":0.9229999780654907},{"id":"https://openalex.org/keywords/niacin","display_name":"nicotinic acid","score":0.9179999828338623},{"id":"https://openalex.org/keywords/propranolol","display_name":"propranolol","score":0.9959999918937683},{"id":"https://openalex.org/keywords/digoxin","display_name":"digoxin","score":0.996999979019165},{"id":"https://openalex.org/keywords/ldl-cholesterol-lowering","display_name":"LDL cholesterol lowering","score":0.8009999990463257},{"id":"https://openalex.org/keywords/biliary-excretion","display_name":"biliary excretion","score":0.8809999823570251}],"concepts":[{"id":"https://openalex.org/C2778417548","wikidata":"https://www.wikidata.org/wiki/Q417942","display_name":"Fluvastatin","level":3,"score":0.9416371583938599},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.736046314239502},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.7257184982299805},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7005006074905396},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.6883070468902588},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6659421920776367},{"id":"https://openalex.org/C2778697171","wikidata":"https://www.wikidata.org/wiki/Q418006","display_name":"Cholestyramine","level":3,"score":0.5790513157844543},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5601267218589783},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3487473726272583},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3432292938232422},{"id":"https://openalex.org/C2778163477","wikidata":"https://www.wikidata.org/wiki/Q43656","display_name":"Cholesterol","level":2,"score":0.24435245990753174},{"id":"https://openalex.org/C2776329913","wikidata":"https://www.wikidata.org/wiki/Q670131","display_name":"Simvastatin","level":2,"score":0.07506608963012695},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077340","descriptor_name":"Fluvastatin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000375","descriptor_name":"Aging","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000375","descriptor_name":"Aging","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002792","descriptor_name":"Cholestyramine Resin","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D002792","descriptor_name":"Cholestyramine Resin","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D004032","descriptor_name":"Diet","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004077","descriptor_name":"Digoxin","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D004077","descriptor_name":"Digoxin","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005229","descriptor_name":"Fatty Acids, Monounsaturated","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D005229","descriptor_name":"Fatty Acids, Monounsaturated","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006937","descriptor_name":"Hypercholesterolemia","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D008077","descriptor_name":"Lipoproteins, LDL","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009525","descriptor_name":"Niacin","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D009525","descriptor_name":"Niacin","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011433","descriptor_name":"Propranolol","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D011433","descriptor_name":"Propranolol","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D012727","descriptor_name":"Sex Characteristics","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014280","descriptor_name":"Triglycerides","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D019161","descriptor_name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1093/ajh/6.11.375s","doi":"https://doi.org/10.1093/ajh/6.11.375s","is_oa":false,"landing_page_url":"https://doi.org/10.1093/ajh/6.11.375s","pdf_url":null,"source":{"id":"https://openalex.org/S128891601","display_name":"American Journal of Hypertension","issn_l":"0895-7061","issn":["0895-7061","1941-7225"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Hypertension","raw_type":"journal-article"},{"id":"pmid:8297546","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/8297546","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American journal of hypertension","raw_type":"Clinical Trial"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.875.7162","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.875.7162","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://ajh.oxfordjournals.org/content/6/11_Pt_2/375S.full.pdf","raw_type":"text"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2279272627","https://openalex.org/W2025557550","https://openalex.org/W2010683803","https://openalex.org/W2116222603","https://openalex.org/W2092944569","https://openalex.org/W2147636174","https://openalex.org/W2113799985","https://openalex.org/W2000723497","https://openalex.org/W2331647326","https://openalex.org/W1988368657"],"abstract_inverted_index":{"Fluvastatin":[0],"sodium":[1],"(Lescol)":[2],"is":[3,20,31,70],"the":[4,25,38,73,81,86,98,113,125,131,145,247],"first":[5],"synthetic":[6],"3-hydroxy-3-methylglutaryl-coenzyme":[7],"A":[8,107],"(HMG-CoA)-reductase":[9],"inhibitor":[10],"to":[11,105,144,168,236],"be":[12],"studied":[13],"extensively":[14],"in":[15,97,123,138,176,180,217],"humans.":[16],"Absorption":[17],"of":[18,27,34,46,57,64,68,88,100,103,109,127,157,163,199,249],"fluvastatin":[19,69,91,149,189,200,215,230,234],"complete":[21],"and":[22,54,183,190,197,224,233],"unaffected":[23],"by":[24,37],"presence":[26],"food.":[28],"Systemic":[29],"exposure":[30],"limited":[32],"because":[33],"extensive":[35],"sequestration":[36],"liver":[39],"and/or":[40],"first-pass":[41],"metabolism,":[42],"a":[43,65,155,164,169,177,194,237],"plasma":[44,148,231],"half-life":[45],"approximately":[47],"30":[48],"min,":[49],"no":[50,55,120,202,227,244],"circulating":[51],"active":[52],"metabolites,":[53],"accumulation":[56],"drug":[58,110],"during":[59],"chronic":[60],"dosing.":[61],"Approximately":[62],"95%":[63],"single":[66,165],"dose":[67,167],"excreted":[71],"via":[72],"biliary":[74],"route":[75],"with":[76,112,172,188,222,252],"less":[77],"than":[78],"2%":[79],"as":[80,154],"parent":[82],"compound.":[83],"Studies":[84],"investigating":[85],"effect":[87,136,245],"food":[89],"on":[90,204,229,246],"pharmacokinetics":[92],"have":[93],"demonstrated":[94,193,207,226],"marked":[95],"reductions":[96],"rate":[99,196],"bioavailability":[101,128],"(Cmax)":[102],"40%":[104],"60%.":[106],"comparison":[108],"administration":[111],"evening":[114],"meal":[115],"or":[116,134,160],"at":[117],"bedtime":[118],"revealed":[119],"significant":[121],"differences":[122],"either":[124,158],"extent":[126,198],"(area":[129],"under":[130],"curve;":[132],"AUC)":[133],"pharmacodynamic":[135],"[reduction":[137],"low-density":[139],"lipoprotein":[140],"cholesterol":[141],"(LDL-C)].":[142],"Relative":[143],"general":[146],"population,":[147],"concentrations":[150],"do":[151],"not":[152],"vary":[153],"function":[156],"age":[159],"gender.":[161],"Administration":[162],"40-mg":[166],"patient":[170,238],"population":[171,239],"hepatic":[173],"insufficiency":[174],"resulted":[175],"2.5-fold":[178],"increase":[179],"both":[181],"AUC":[182,248],"Cmax.":[184],"Drug":[185],"interaction":[186],"studies":[187,221],"cholestyramine":[191],"(CME)":[192],"lower":[195],"bioavailability;":[201],"impact":[203],"efficacy":[205],"was":[206,210],"when":[208],"CME":[209],"given":[211],"4":[212],"h":[213],"before":[214],"dosing":[216],"clinical":[218],"trials.":[219],"Interaction":[220],"niacin":[223],"propranolol":[225],"effects":[228],"levels,":[232],"administered":[235],"chronically":[240],"receiving":[241],"digoxin":[242,250],"had":[243],"compared":[251],"controls.(ABSTRACT":[253],"TRUNCATED":[254],"AT":[255],"250":[256],"WORDS)":[257]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2025422355","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":3},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
